Intrinsic Value of S&P & Nasdaq Contact Us

Atai Beckley N.V ATAI NASDAQ

NASDAQ Global Market • Healthcare • Medical - Pharmaceuticals • NL • USD

SharesGrow Score
56/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.75
+193.8%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Atai Beckley N.V (ATAI) has a negative trailing P/E of -1.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 22.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -56.92%, forward earnings yield 4.44%.

Criteria proven by this page:

  • VALUE (100/100, Pass) — analyst target implies upside (+193.8%).
  • Forward P/E 22.5 — analysts expect a return to profitability with estimated EPS of $0.18 for FY2030.
  • Trailing Earnings Yield -56.92% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 4.44% as earnings recover.
  • Analyst consensus target $11.75 (+193.8% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
56/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
56/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — ATAI

Valuation Multiples
P/E (TTM)-1.8
Forward P/E22.5
PEG RatioN/A
Forward PEGN/A
P/B Ratio5.23
P/S Ratio170.22
EV/EBITDA-5.4
Per Share Data
EPS (TTM)$-2.10
Forward EPS (Est.)$0.18
Book Value / Share$0.71
Revenue / Share$0.01
FCF / Share$-0.36
Yields & Fair Value
Earnings Yield-56.92%
Forward Earnings Yield4.44%
Dividend Yield0.00%
Analyst Target$11.75 (+193.8%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2019 -214.6 0.00 51.65 0.00 -
2020 -17.9 -0.04 33.41 0.00 -
2021 -7.3 -0.31 3.25 60.17 -
2022 -2.7 -0.28 1.59 1,777.74 -
2023 -5.6 0.08 0.92 713.23 -
2024 -1.4 -0.01 1.83 691.60 -
2025 -1.4 -0.01 4.18 226.59 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2019 $-3.23 $0.00 $-17.48M -
2020 $-17.57 $0.00 $-102.12M -
2021 $-0.83 $20.38M $-132.61M -650.8%
2022 $-0.91 $233K $-141.41M -60691.4%
2023 $-0.25 $314K $-40.22M -12810.2%
2024 $-0.93 $308K $-149.27M -48464%
2025 $-2.91 $4.09M $-660.05M -16142%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.47 $-0.76 – $-0.37 $430.77K $430.77K – $430.77K 9
2027 $-0.48 $-0.72 – $-0.39 $140K $140K – $140K 8
2028 $-0.47 $-0.77 – $-0.29 $17.83M $17.83M – $17.83M 11
2029 $-0.28 $-0.28 – $-0.28 $164.61M $164.61M – $164.61M 4
2030 $0.18 $0.18 – $0.18 $406.92M $406.92M – $406.92M 4
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message